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HLA-A*6801 exhibits several unusual features. First, it is known to bind weakly to CD8
due to the presence of an A245V substitution in the a3 domain. Second, it is able to
accommodate unusually long peptides as a result of peptide 'kinking' in the binding
groove. Third, CD8
+ cytotoxic T lymphocytes that recognise HLA-A*6801-restricted
antigens can tolerate substantial changes in the peptide sequence without apparent loss
of recognition. In addition, it has been suggested that HLA-A68-restricted TCR might
bind with higher affinity than other TCR due to their selection in the presence of a
decreased contribution from CD8. Here we (1) examine monoclonal Tcell recognition
of an HLA-A*6801-restricted HIV-1 Tat-derived 11-amino acid peptide (ITKGLGISYGR)
and natural variant sequences thereof; (2) measure the affinity and kinetics of a TCR/
pHLA-A68 interaction biophysically for the first time, showing that equilibrium binding
occurs within the range previously determined for non-HLA-A68-restricted TCR
(KD approx. 7 lM); and (3) show that “normalization” of the non-canonical HLA-
A*6801 CD8-binding domain enhances recognition of agonist peptides without
inducing non-specific activation. This latter effect may provide a fundamental new
mechanism with which to enhance T cell immunity to specific antigens.
Supporting information for this article is available at
http://www.wiley-vch.de/contents/jc_2040/2007/36243_s.pdf
Introduction
The MHC class I (MHCI) antigen processing pathway
presents short peptides, derived from endogenously
expressed proteins, at the cell surface [1]. The highly
variable complementarity-determining regions of TCR
on the surface of CD8
+ cytotoxic T lymphocytes (CTL)
interact with both the peptide and the peptide-binding
platform of the MHCI molecule to confer peptide-MHCI
(pMHCI) specificity [2]. Almost all nucleated cells
express MHCI, thereby enabling CTL to scan for internal
anomalies. The ability of CTL to detect and destroy cells
displaying aberrant-self or non-self peptides makes
them key determinants of immunity to neoplastic cells
and intracellular pathogens.
Other 'accessory' molecules at the T cell surface also
contribute to antigen recognition in concert with the
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stimulatory signals while others serve to aid cellular
adhesion. Notably, the recognition of T cell antigens by
theabTCRisuniqueamong receptor-ligandinteractions
asitinvolvesengagementofa'co-receptor'moleculethat
binds to the MHC at a largely invariant site distal from
the TCR-docking platform [3–5]. The co-receptor for
MHCIantigens,CD8, isknowntofacilitatetheprocessof
antigen recognition by a number of mechanisms [6–8].
Human CD8 makes contacts with the MHCI
a3 domain, particularly the a3 'loop' (residues
225–232), the underside of the a2 domain
(residues 115, 122, 128 and 198) and b2-microglobulin
[3]. This region is largely invariant and human MHCI
molecules are known to exhibit similar affinities for CD8
(KD=100–200 lM) [9]. Avery small minority of human
MHCI molecules, HLA-A*68, -B*48 and -B*81, differ in
their a3 domain sequence. In HLA-A*68, a valine
residue at position 245 replaces the standard alanine
present in other MHCI molecules; in HLA-B*48 and
-B*81, residue 245 is a threonine. Molecular modeling
based on the structures of HLA-A*0201, HLA-A*6801
and the HLA-A*0201/CD8 cocrystal predicts that the
larger valine residue at position 245 in HLA-A*6801
distorts the a3 loop of the molecule, resulting in a less
energetically favorable interaction with CD8 [3, 9]. This
is presumably also true for the threonine residue at
position 245asHLA-B*4801showsgreatlyreduced CD8
binding (KD>1000 lM) [9]. Substitution of the cano-
nical alanine residue at position 245 of HLA-A*0201 for
valine or threonine confirms the effects of these
mutations and increases the KD of CD8 binding from
approximately 130 lM to 500 lM and 470 lM, respec-
tively [9].
HLA-B*48 and -B*81 are uncommon in Caucasian
populations and CTL responses restricted by HLA-B*48
and -B*81 molecules have yet to be studied in detail.
HLA-A*68-restricted CTL, especially those restricted by
HLA-A*6801,havebeenof interestformanyyearsdueto
the reduced CD8 binding of this molecule. Indeed,
studies of HLA-A*6801 (formerly known as HLA-
Aw68.1) have greatly improved our understanding of
pMHCI [10–12].
HLA-A*6801 (referred to as HLA-A68 from hereon)
is known to bind CD8 very weakly (KD*1000 lM) [9,
13]. In addition to reduced CD8 binding, HLA-A68
exhibits other unusual features. First, it is able to restrict
unusually long peptide antigens as a result of 'kinking' in
the binding groove [11]. Second, HLA-A68-restricted
CTL are capable of accepting a remarkable degree of
residue substitution in the bound peptide [14]. A CTL
line specific for the influenza epitope KTGGAIYKR was
able to recognise efficiently a peptide alanine-substi-
tuted at all but a single non-MHC anchor position
(ATAAAIAAR) [14]. Just 25 million human TCR [15]
have to cover all the possible MHC-restricted peptides
generated from permutations of the 20 proteogenic
amino acids.As aresult, anextremelyhigh levelof cross-
reactivity is essential for effective T cell immunity [16].
Our recent findings show that the MHCI/CD8 interac-
tion controls optimal levels of T cell cross-reactivity
(Laugel et al., in preparation). Indeed, introduction of
the A245V substitution in HLA-A*0201 substantially
reduces the number of variant antigens that can be
recognised by HLA-A*0201-restricted CTL clones (Lau-
gel et al., in preparation) and we suggest that HLA-A68-
restricted TCR might incorporate increased binding
degeneracy in order to compensate for their weakened
CD8 binding and allow coverage all potential HLA-A68-
restricted peptides. Third, it has been suggested that
HLA-A68-restricted TCR might bind cognate antigen
with higher affinity than those restricted by MHCI
molecules with a canonical CD8-binding domain due to
their thymic selection in the presence of a reduced
pMHCI/CD8 interaction [17].
Herein, we measure the affinity and kinetics of a
TCR/pHLA-A68 interaction biophysically for the first
time. In addition, we normalize the non-canonical CD8-
binding domain of HLA-A68 and undertake the first
studyof the biological effects of increasing the affinityof
the pMHCI/CD8 interaction while TCR/pMHCI inter-
actions remain faithful.
Results
Recognition of natural HIV-1 variants by
HLA-A68-resticted Tat-specific CTL
SC21, a patient with primary HIV-1 infection, made a
dominant CTL response to the patient-autologous Tat-
derived peptide ITKGLGISYGR through HLA-A68.
Residue 2 and the C-terminal residue act as anchors
for HLA-A68 [11]. Neither of the two 10-mer peptides
contained within the 11-mer ITKGLGISYGR epitope
were antigenic [18]. Consequently, this HIV-1 Tat-
derived peptide is longer than normal MHCI-presented
peptides and is expected to bulge out from the HLA-A68
a1/a2 peptide-binding platform. Such bulging of
peptides bound to HLA-A68 has previously been
documented [11]. The patient-autologous Tat epitope
sequence (ITKGLGISYGR) differed from the HIV-LAI
reference sequence at positions 1 and 4 (TTKALGI-
SYGR). A CTL line grown from a SC21 sample taken at
day 297 following the onset of symptoms was used to
produce a vigorously growing CTL clone (c23).
At the first time point that patient virus was
sequenced (day 60 following the onset of symptoms),
four out of 13 clones encoded a T at position 1 of the
ITKGLGISYGRepitope[19].The1Tsequencewasabsent
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onset of symptoms). Thus, it is possible that the founder
virus in SC21 encoded the 1T sequence. We analyzed
responses to the patient 'index' sequence (ITKGLGI-
SYGR), the LAI reference sequence (TTKALGISYGR),
the patient variant (TTKGLGISYGR) and the intermedi-
ate (ITKALGISYGR) sequence (Fig. 1). For the sake of
ease, these peptides are described with reference to the
position within the patient epitope that is modified (i.e.
as 'index', 1T/4A, 1Tand 4A, respectively) from hereon.
The 1T variant was consistently recognised at lower
concentrations than the 'index' peptide in functional
assays of degranulation and cytokine/chemokine re-
lease (Fig. 1). The difference in activation potential
between the index and 1T sequences varied between
effector functions (Fig.1), being minimal for degranula-
tion, intermediate for MIP-1a/b and greatest for IFN-c
and TNF-aproduction; this pattern conforms tothe level
of TCR triggering required to induce these effector
functions (degranulation/killing < MIP < IFN-c) [20,
21]. The fact that the 1T variant acts as the best agonist
may also indicate that this sequence represents the
founder virus that initially induced the HLA-A68-
restricted Tat response in SC21, although retrospective
confirmation of this is not possible.
Manufacture and biophysical analysis of soluble
HLA-A68-restricted TCR
The TCR from c23 was manufactured as a soluble
protein; the sequence of the TCR alpha and beta chains
highlighting the complementarity-determining region
loops is shown in Supplementary Fig.1. All the proteins
utilized in this study were of high purity (Fig. 2A). Gel-
shift analysis with soluble c23 TCR and HLA-A68-
ITKGLGISYGR showed that >90% of the c23 TCR bound
to its cognate ligand (Fig. 2B). Surface plasmon
resonance analysis showed that the two antigens that
occurred in the patient, HLA-A68-ITKGLGISYGR and
HLA-A68-TTKGLGISYGR, bound to c23 TCR with KDs of
7.00.68 lM and 2.50.2 lM, respectively (Fig. 3).
These affinities are within the normal range
(KD=1–10 lM) [2] that we have observed for eight
antiviral HLA class I-restricted TCR (Cole et al., in
preparation). That the c23 TCR bound to the 1T peptide
with higher affinity than the index peptide, attributable
primarily to a slower off-rate (Fig. 4), is consistent with
the fact that this sequence is a better agonist for c23 CTL
according to current kinetic models of T cell activation
(Fig. 1) [22, 23].
Enhancement of the HLA-A68/CD8 interaction
We manufactured two mutated forms of HLA-A68 in
order to increase or abrogate CD8 binding. We have
previously examined CD8 binding to HLA-A68 [13, 18].
Figure 1. Activation profile of CTL clone c23 in response to various agonist ligands. Six different read-outs were used to assess the
response of c23 CTL to four different agonist peptides in a 4-h dose-response assay; cells and supernatants were harvested
separately. (A) The level of degranulation marker CD107a up-regulation on CD8
+ cells was determined by flow cytometry. (B–F)
Release of 11 cytokines and chemokines in the cell supernatant was estimated with bead arrays; substantial quantities were
detected for 5/11 of these lymphokines.
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[13]. A double substitution of D227 and T228 to K and A,
respectively (DT227/8KA), abrogates the interaction
with CD8 (KD>10 mM), while a V245-to-A (V245A)
substitution increases the affinity of this interaction
(KD=102 lM) [13]. Multimeric forms of DT227/8KA
HLA-A68, WT HLA-A68 and CD8-enhanced (V245A)
HLA-A68 antigens all bind to cell surface TCR equally
well, suggesting that these substitutions do not interfere
with the a1/a2 peptide-binding platform of the HLA-
A68 molecule contacted by the TCR ([13] and data not
shown). In order to confirm that these mutations do not
affect TCR binding, we performed surface plasmon
resonance experiments using HLA-A68, DT227/8KA
HLA-A68 and V245A HLA-A68 folded with the ITKGL-
GISYGR index peptide. All three HLA-A68 antigens
bound the c23 TCR with equivalent affinity (KD=7 lM;
Fig.3A,C, D)butshowedtheexpecteddifferencesinthe
binding of CD8aa molecules ([13] and data not shown).
Biological effects of an enhanced HLA-A68/CD8
interaction
The ability to 'normalize' CD8 binding of HLA-A68 by
V245A substitution provided a unique opportunity to
examine the biological effects of enhanced CD8 binding
for the first time. Full-length DT227/8KA HLA-A68, WT
HLA-A68 and V245A HLA-A68 were expressed in C1R
cells by stable transfection using previously described
methodology [13]. Peptide-pulsed targets expressing
HLA-A68 with enhanced CD8 binding were recognised
by cognate CTL at lower antigen concentrations and
induced greater production of IFN-c, MIP-1b and
RANTES from these CTL at equivalent peptide concen-
trations compared to target cells expressing WT HLA-
A68 (Fig. 5). Enhancing CD8 binding did not alter the
recognition pattern of natural HIV-1 Tat variants
(Fig. 6). Thus, increasing the interaction between
HLA-A68 and CD8 results in a marked improvement
in the functional recognition of cognate antigen.
Importantly, our data (Fig. 5, 6 and not shown) show
no background activation of CTL by targets expressing
V245A 'CD8-enhanced' HLA-A68 and rule out the
possibility that c23 is able to recognise natural levels
ofselfpeptidespresentedinthecontextof thismolecule.
Discussion
In this report, we describe the manufacture and
characterization of the first HLA-A68-restricted TCR.
This TCR was shown to bind to cognate antigen with an
affinity well within the normal range for anti-viral TCR
restricted by other MHCI molecules. Thus, the selection
of TCR in the presence of impaired CD8 binding need
not result in supranormal TCR/pMHCI affinities. At
11 amino acids, the HLA-A68-restricted peptide recog-
nised by the c23 TCR is unusually long for MHCI-
restricted antigens and is believed to kink away from the
peptide binding platform [11]. This may necessitate
unusual TCR docking as has recently been described for
a super-bulged 13-amino acid Epstein–Barr virus-
derived peptide restricted by HLA-B*3508 [24]. The
requirement for the unusual docking associated with
bulging peptides may bias the TCR repertoire and result
in limited TCR diversity [25]. The realization that
peptides of greater than ten amino acids in length can be
presented by MHCI molecules and recognised by
cognate TCR has led to recent calls to broaden the
algorithms widely used to predict MHCI-binding pep-
tides [26]. To date, there has been no systematic and
unbiased comparison between HLA-A68, -B35 and other
MHCI molecules and it is therefore not possible to know
whether HLA-A68 and -B35 are unusual in binding long
peptides.
We found that “normalizing” the CD8 binding of
HLA-A68 resulted in enhanced recognition of agonist
peptides without resulting in recognition of self peptide-
HLA-A68 complexes (Fig. 5, 6). CD8-enhanced pMHCI
ligands were recognised at lower concentration and
induced substantially better effector function for a given
quantityof antigen(Fig.5, 6). CD8 is known tofacilitate
Figure2.Thequalityandbiologicalactivityoftheproteinsused
in this study. (A) SDS-PAGE purity analysis of c23 TCR and each
A68 variant. The numbered lanes on the gel are as follows:
1: Seeblue molecular markers; 2: c23 TCR; 3: A68 WT index;
4: A68 WT 1T; 5: A68 245A index; 6: A68 227/8KA index. (B)
Native gel analysis of complex formation between c23 TCR and
A68 WT index. Different molar ratios of c23 and A68 were
mixed together in order to determine the optimum conditions
for complex formation. The numbered lanes on the gel are as
follows: 1: A68 WT index; 2: c23 TCR; 3: c23 TCR 4:1 A68 WT
index; 4: c23 TCR 3:1 A68 WT index; 5: c23 TCR 2:1 A68 WT
index; 6: c23 TCR 1:1 A68 WT index; 7: c23 TCR 1:2 A68 WT
index; 8: c23 TCR 1:3 A68 WT index. As the ratio of A68 WT
index increases compared to c23 TCR, the amount of c23 TCR
forming the complex also increases. At a molecular ratio of c23
TCR 1:1 A68 WT index, >90% of c23 TCR has formed the
complex.
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Cofthec23TCR.Bindingto:(A)A68WTcomplexedtoindexpeptide,(B)A68WTcomplexed
to 1T peptide, (C) A68 245A complexed to index peptide and (D) A68 227/8KA complexed to index peptide. Ten serial dilutions of
concentrated TCR were injected at 30 lL/min for 45-s association periods. The solid lines for each binding response were
calculated assuming 1:1 Langmuir binding [AB = B*ABMAX/(KD + B)] and the data were analyzed using a global fit algorithm
(BIAevaluation
TM 3.1) to calculate Kon and Koff values. The c23 TCR kinetics for each A68 variant with the index peptide were
virtuallyidenticalwithKoff valuesof0.32–0.36 s
–1andKonvaluesof4.610
4 M
–1s
–1and5.110
4 M
–1s
–1.FortheA68WT1Tcomplex,
thec23TCRboundwitha Kon similarto thatoftheindex-complexedA68variantsof5.410
4 M
–1s
–1. Thestrongeraffinityobserved
was due to an extended Koff of 0.13 s
–1.
Figure3.SurfaceplasmonresonanceofHLA-A68-restrictedc23TCR.Equilibriumbindingresponsesat25
Cofthec23TCRagainst:
(A) A68 WT complexed to index (ITKGLGISYGR) peptide, (B) A68 WT complexed to 1T (TTKGLGISYGR) peptide, (C) A68 245A
complexed to index peptide and (D) A68 227/8KA complexed to index peptide. Ten serial dilutionswere carried out in triplicate for
each equilibrium experiment. The average response for each concentration is plotted with standard deviation (n=3). The
equilibrium binding constant (KD) values are plotted using a nonlinear curve fit [y =( P 1x)/(P2 + x)]. c23 TCR binding to each A68
variant with the index peptide was identical with a KD of 7 lM. c23 TCR bound about three times stronger to the A68 WT 1T
complex with a KD of 2.4 lM. Introducing the DT227/8KA or the V245A mutations into HLA-A68 abrogates (KD>10 000 lM) or
enhances (KD=102 lM) the already weak HLA-A68/CD8 interaction (KD = 980 lM), respectively [13], without affecting the affinity
of the TCR/pMHCI interaction. These mutations therefore do not disrupt the a1/2 peptide-binding platform of the molecule that is
recognised by the TCR.
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mechanisms [6–8]. To date, it has been established that
CD8 (1) recruits the TCR to specific membrane domains
believed to be privileged sites for TCR-mediated signal
transduction [27]; (2) recruits essential signaling
molecules to the intracellular side of the TCR/CD3/f
complex [28, 29]; and (3) stabilizes the TCR/pMHCI
interaction at the cell surface [30, 31]. It is not yet clear
whether CD8 has other roles in antigen recognition.
CD8-mediated topographical TCR organisation is
thought to be a function of a direct interaction between
thesemolecules [27,32, 33]and isnottherefore likelyto
depend on the pMHCI/CD8 interaction. Thus it is likely
that the effects we observe are the result of enhanced
TCR dwell times and superior intracellular signaling.
Our recent experiments with HLA-A2 predict that
V245A substitution of HLA-A68 will enhance TCR mean
dwell time by *15% more than that afforded by a WT
interaction [31]. It is therefore likely that there will be
some ligands that fall within the narrow window of
TCR/pMHCI dwell times that allow them to be 'null' in
the context of HLA-A68 but weak agonists in the context
of V245A HLA-A68. Such ligands are likely to be rare
amongst the myriad of possible HLA-A68-restricted
peptides encoded by the 20 proteogenic amino acids.
That V245A HLA-A68-expressing targets do not activate
c23 CTL in the absence of added peptide is good
evidence that there are no self-expressed ligands for this
TCR that occur within this narrow affinity window.
In summary, our results indicate that there may be
scope for improving the recognition of HLA-A68-
restricted antigens. We have recently demonstrated that
'CD8 enhancement' can be engineered into any human
MHCI molecule and, therefore, any MHCI-restricted
antigen [31]. Experiments are underway to determine
whether the improved antigenicity of 'CD8-enhanced'
antigens is a general phenomenon. Our findings suggest
anovelmechanismthatcouldenableboostingofspecific
cytotoxic immunity, an approach that might be espe-
cially pertinent in the context of anti-tumor CTL
responses. In addition, CD8 enhancement might prove
useful in the setting of vaccination strategies to enhance
the generation of pMHCI-restricted peptide-specific CTL
responses.
Figure 6. Increasing the HLA-A68/CD8 interaction does not alter the CTL recognition pattern of peptide variants. HLA-A68-
restricted c23 ITKGLGISYGR-specific CTL (10
3) were incubated with 2.510
4 C1R transfectants in a 3.5-h ELISPOT assay. Targets
expressing identical levels of DT227/8KAHLA-A68 (A), WT HLA-A68 (B) or V245A HLA-A68 (C) werepulsedwith indicated amounts
of index peptide or naturally occurring variants as shown in the key. Error bars show standard deviation from the mean of three
replicate assays, although in most cases the error is smaller than the plot symbol.
Figure 5. Increasing the HLA-A68/CD8 interaction enhances T cell sensitivity and response magnitude. C1R target cells expressing
identical levels of WT HLA-A68, DT227/8KA HLA-A68 or V245A HLA-A68 were pulsedwith the indicated concentrations of peptide
and used to stimulate c23 ITKGLGISYGR-specific CTL. Activation read-outs were IFN-c ELISPOT (A) using 2.510
2 CTL and
2.510
4 C1R transfectants at 37
C in a 4-h assay, and MIP-1b (B) or RANTES (C) ELISA [20] of supernatant after 2.510
4 CTL were
incubated with 2.510
4 C1R transfectants at 37
C for 4 h. Assays were performed as described previously [13]. Error bars show
standard deviation from the mean of three replicate assays, although in most cases the error is smaller than the plot symbol.
Emma Gostick et al. Eur. J. Immunol. 2007. 37: 479–486 484
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euMaterials and methods
Cloning of HLA-A68-restricted HIV-1 Tat-specific CTL
Patient SC21, a 37-year-old homosexual male, presented with
primary HIV-1 infection shortly after a well-documented high-
risk sexual exposure [19]. The patient mounted substantial
Tcell responses to four MHCI-restricted antigens as quantified
by IFN-c ELISPOT in the 10-month period following the onset
of symptoms [19]. The numerically dominant response
(5000–8000 spot-forming cells/10
6 peripheral blood lympho-
cytes) was specific for an epitope from the HIV-1 Tat
transactivator protein [19]. SC21 peripheral blood lympho-
cytes were used to map this epitope directly ex vivo with an
adapted IFN-c ELISPOT assay and a library of eight 20-amino
acid peptides from the Tat protein that overlapped by ten
residues [18]. An HLA-A68-restricted response to the Tat4
peptide (Tat residues 31–50, FHCQVCFTTKALGISYGRKK) was
observed.
Subsequent sequence analysis of the patient's autologous
virus identified two amino acid changes compared to the HIV-
LAI reference sequence that was used to make the peptide
library (38I and 41G) [19]. Responses to the autologous Tat4
peptide were consistently better than to the HIV-LAI sequence
[18]. Further analysis, using the patient-autologous sequence,
narrowed down the peptide antigen to an 11-amino acid
epitope (ITKGLGISYGR) [18]. Residue 2 and the C-terminal
residue act as anchors for HLA-A68 [11]. Neither of the two
10-mer peptides contained within the 11-mer ITKGLGISYGR
epitopewereantigenic[18].ACTLlinewasgrownfromaSC21
sample taken at day 297following the onsetof symptoms. This
CTL line was then cloned by limiting dilution at 0.3 cells/well
to produce a vigorously growing CTL clone (c23).
Target cells
The manufacture of C1R cells expressing HLA-A68 is described
elsewhere [13]. Cells were cloned and tested with relevant
antibodies to ensure that they expressed identical levels of
MHCI on their surface.
Surface plasmon resonance, soluble pMHCI and TCR
manufacture
Soluble pMHCI manufacture, tetramerization and biophysical
studies were performed as previously described [31]. The
mutations in HLA-A68 and the biophysical validation of their
effects are published elsewhere [13, 31]. In order to obtain the
sequence of an HLA-A68-restricted TCR, cDNA from c23 was
used as a template in 42 separate PCR using a primer set to
cover all TCRAV and TCRAJ genes. Only one reaction
generated a product. Sequencing confirmed a TCR a chain
made fromthe TCRAV 14 gene with a TCRAJ 20joining region
(IMGT nomenclature). The TCRB sequence was generated bya
single PCR with a combined primer set [34]. The reaction
yielded a single product. Sequence analysis showed a
TCRBV 7-9 gene with a TCRBJ 1-1 joining region. The TCR
a chain was cloned into pGMT7 expression vector as a fusion
construct with the c-jun leucine zipper region [35]. A TCR
b chain pGMT7 expression vector was constructed to express
the TCR chain as a fusion with the v-fos leucine zipper [35].
Expression vectors were transformed into Escherichia coli
Rosetta DE3 (pLysS) and protein was produced as inclusion
bodies by inducing protein expression with 0.5 mM isopropyl-
b-D-thiogalactopyranoside.
Following cell harvest by centrifugation, inclusion bodies
were isolated by sonication and purified with three successive
detergent washes using 0.5% Triton X-100. Inclusion bodies
were given a final wash in resuspension buffer to remove any
detergent before being resolubilized in guanidine solution
(6 M guanidine, 50 mM Tris pH 8.1, 100 mM NaCl, 10 mM
EDTA, 10 mM dithiothreitol). Insoluble material was pelleted
by centrifugation and the supernatant stored at –80
C. TCR-
zipper chains were refolded at a 5:1 ratio of a:b chain. Each
solubilized inclusion body chain was diluted to 5 mg/mL in
guanidine solution. To ensure complete denaturation, dithio-
threitol was added to a concentration of 10 mM and chains
were incubated at 37
C for 30 min. Refolding of soluble TCR
was initiated byinjecting the dissolved a and b chain inclusion
bodies simultaneously into a vigorously stirring refolding
buffer (5 M urea, 0.4 M L-arginine, 100 mM Tris pH 8.1,
6.5 mM cysteamine-HCl, 3.7 mM cystamine di-hydrochloride)
chilled to 4
C, to a final concentration of 60 mg/L.
The solution was left for 3 h, then dialyzed for 24 h against
ten volumes of demineralized water, followed by ten volumes
of10 mM Tris pH 8.1.All dialysis steps were carriedoutat 4
C.
Dialyzed TCR was isolated from impurities by filtering and
loading ontoa POROS50 HQ anion exchange column (Applied
Biosystems). The column was washed with 10 mM Tris pH 8.1
and bound protein was eluted with a NaCl gradient (0–1 M) in
the same buffer. Correctly refolded protein was confirmed by
reducedandnon-reducedsodiumdodecylsulfate(SDS)-PAGE.
Fractions containing correctly refolded TCR were pooled,
concentrated and further purified on a Superdex 200 gel
filtration column (Amersham Biosciences, Uppsala, Sweden)
in HEPES-buffered saline (HEPES pH 7.4, 150 mM NaCl,
3 mMEDTA).Thefinalpurifiedc23TCRwasanalyzedbySDS-
PAGE in reducing and non-reducing conditions. Peak fractions
were pooled and concentrated prior to BIAcore
TM surface
plasmon resonance studies.
Measurement of CTL degranulation, cytokine and
chemokine release
Antigen-presenting cells(210
4 Hmy.2C1RBcellstransfected
with HLA-A68) were pre-pulsed with the indicated concentra-
tions of peptide and washed twice with serum-free RPMI
medium. CTL (510
3) were added in each assay well and
incubated for 4 h at 37
C in 96-well plates in presence of
fluorescein isothiocyanate-conjugated anti-CD107a mAb (BD
Pharmingen) and Golgi-stop (BD Pharmingen) diluted
1 in 100 and 1 in 3000, respectively. Cells were pelleted by
centrifugation and separated from the supernatants before
staining with anti-CD8 mAb directly conjugated to allophyco-
cyanin (Becton Dickinson) and 7-amino-actinomycin dye
(Becton Dickinson). Supernatants were assayed by human
Th1/Th2 cytokine cytometric bead array for IL-2, IL-4, IL-6,
IL-10, IFN-c and TNF-a secretion, and chemokine cytometric
bead array for monocyte chemotactic protein-1, MIP-1a,
MIP-1b, IL-8 and RANTES secretion (BD Pharmingen)
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performed using a FACSCalibur (Becton Dickinson) flow
cytometer. IFN-c ELISPOT assays and chemokine ELISA were
conducted as described previously [13, 20].
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